Explore
Validate
Learn18098-1-AP
antibody from Proteintech Group
Targeting: B3GNT3
B3GN-T3, B3GNT-3, beta3Gn-T3, HP10328, TMEM3
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 18098-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#18098-1-AP, RRID:AB_10596928
- Product name
- B3GNT3 antibody
- Antibody type
- Polyclonal
- Description
- B3GNT3 antibody (Cat. #18098-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references B3GNT3: A prognostic biomarker associated with immune cell infiltration in pancreatic adenocarcinoma.
Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma.
B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer.
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.
B3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer.
Kong K, Zhao Y, Xia L, Jiang H, Xu M, Zheng J
Oncology letters 2021 Feb;21(2):159
Oncology letters 2021 Feb;21(2):159
Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma.
Leng X, Wei S, Mei J, Deng S, Yang Z, Liu Z, Guo C, Deng Y, Xia L, Cheng J, Zhao K, Gan F, Li C, Merrell KW, Molina JR, Metro G, Liu L
Translational lung cancer research 2021 Feb;10(2):965-980
Translational lung cancer research 2021 Feb;10(2):965-980
B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer.
Gao L, Zhang H, Zhang B, Zhu J, Chen C, Liu W
Journal of clinical pathology 2018 Jul;71(7):642-647
Journal of clinical pathology 2018 Jul;71(7):642-647
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.
Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, Chang SS, Lee HH, Chou CK, Liu YL, Yeh HC, Perillo EP, Dunn AK, Kuo CW, Khoo KH, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Huang TH, Sahin AA, Hortobagyi GN, Yoo SS, Hung MC
Cancer cell 2018 Feb 12;33(2):187-201.e10
Cancer cell 2018 Feb 12;33(2):187-201.e10
B3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer.
Zhang W, Hou T, Niu C, Song L, Zhang Y
PloS one 2015;10(12):e0144360
PloS one 2015;10(12):e0144360
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- human placenta tissue were subjected to SDS PAGE followed by western blot with 18098-1-AP(B3GNT3 antibody) at dilution of 1:500
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human colon using 18098-1-AP(B3GNT3 antibody) at dilution of 1:100 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The B3GNT3 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human B3GNT3. This antibody recognizes human, mouse antigen. The B3GNT3 antibody has been validated for the following applications: ELISA, WB, IHC analysis.
